Short-Interval, Low-Dose [ 177 Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 36881610.
- Also identified by DOI 10.1097/RLU.0000000000004612.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man with recurrent glioblastoma who was treated with 2 cycles of low-dose [ 177 Lu]Lu-PSMA after exhausting all available treatment options in the state sector. Baseline imaging demonstrated intense PSMA signal in the known lesion, which was amenable to therapy. The prospect of [ 177 Lu]Lu-PSMA-based therapy for glioblastoma is warranted going forward.
Medical subject headings
- Glioblastoma
- Prostatic Neoplasms, Castration-Resistant